Legend Who Bought Amazon In 1998 Says: Now Is The Time
Wall street legend Chris Rowe says there’s a huge stock market event looming - and he’s revealing his #1 pick for free.
Click here to find out more.
pixel

BCYC Insider Trading (Bicycle Therapeutics)

Insider Ownership Percentage: 17.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,454,644.72

Bicycle Therapeutics Insider Trading History Chart

Bicycle Therapeutics Share Price & Price History

$30.00
▲ +0.48 (1.63%)
As of 06/11/2021 01:00 AM ET
Days: 30 | 90 | 365
Six Tech Stocks That Could Double
5G… blockchain… electric vehicles… There are enough tech opportunities out there to make your head spin! But which ones should you own for the coming tech boom?

Louis Navellier — the analyst who found Microsoft at .38 cents — just released a new report detailing six tech stocks to own today.

Don’t miss your chance to get his latest picks — ticker symbol and all — completely free of charge.
Click here to get your free report today.
pixel

Bicycle Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/6/2021Kevin LeeCEOSell1,716$32.14$55,152.24256,450View SEC Filing Icon  
5/4/2021Kevin LeeCEOSell897$32.03$28,730.91258,125View SEC Filing Icon  
4/30/2021Kevin LeeCEOSell58,919$30.86$1,818,240.34277,229View SEC Filing Icon  
4/28/2021Kevin LeeCEOSell22,495$31.08$699,144.60277,229View SEC Filing Icon  
4/26/2021Kevin LeeCEOSell18,611$31.28$582,152.08273,345View SEC Filing Icon  
4/8/2021Pierre LegaultDirectorSell24,838$31.71$787,612.9824,838View SEC Filing Icon  
4/5/2021Pierre LegaultDirectorSell162$31.07$5,033.34162View SEC Filing Icon  
3/31/2021Nicholas KeenInsiderSell10,000$30.00$300,000.0028,321View SEC Filing Icon  
3/17/2021Pierre LegaultDirectorSell7,784$29.00$225,736.007,784View SEC Filing Icon  
3/15/2021Nicholas KeenInsiderSell217$28.00$6,076.0038,821View SEC Filing Icon  
3/12/2021Nicholas KeenInsiderSell9,783$28.50$278,815.5038,821View SEC Filing Icon  
3/12/2021Pierre LegaultDirectorSell2,216$29.00$64,264.002,216View SEC Filing Icon  
1/19/2021Kevin LeeCEOSell5,000$29.26$146,300.00260,556View SEC Filing Icon  
1/19/2021Lee KalowskiCFOSell15,000$30.00$450,000.0015,000View SEC Filing Icon  
1/15/2021Kevin LeeCEOSell10,000$26.01$260,100.00270,085View SEC Filing Icon  
12/1/2020Lee KalowskiCFOSell7,500$22.50$168,750.007,500View SEC Filing Icon  
11/27/2020Lee KalowskiCFOSell530$20.00$10,600.00530View SEC Filing Icon  
11/25/2020Lee KalowskiCFOSell9,781$20.07$196,304.6717,189View SEC Filing Icon  
11/23/2020Lee KalowskiCFOSell17,189$19.83$340,857.8717,189View SEC Filing Icon  
7/14/2020Plc GlaxosmithklineMajor ShareholderSell1,597$19.27$30,774.19View SEC Filing Icon  
5/28/2019Deborah HarlandDirectorBuy385,714$14.00$5,399,996.00View SEC Filing Icon  
5/28/2019Life Sciences Fund V Lp SvMajor ShareholderBuy385,715$14.00$5,400,010.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Bicycle Therapeutics (NASDAQ:BCYC)

47.55% of Bicycle Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Bicycle Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2021Logos Global Management LP800,000$23.90M2.3%N/A3.329%Search for SEC Filing on Google Icon
5/18/2021Point72 Asset Management L.P.1,577,493$47.12M0.2%+9.7%6.565%Search for SEC Filing on Google Icon
5/18/2021Verition Fund Management LLC240,134$7.17M0.1%+609.7%0.999%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley2,240$67K0.0%-35.5%0.009%Search for SEC Filing on Google Icon
5/18/2021Glenmede Trust Co. NA9,908$0.30M0.0%N/A0.041%Search for SEC Filing on Google Icon
5/17/2021Schonfeld Strategic Advisors LLC11,100$0.33M0.0%N/A0.046%Search for SEC Filing on Google Icon
5/17/2021Janus Henderson Group PLC1,693,658$50.65M0.0%N/A7.049%Search for SEC Filing on Google Icon
5/14/2021Ghost Tree Capital LLC150,000$4.48M1.1%N/A0.624%Search for SEC Filing on Google Icon
5/14/2021FIL Ltd523,201$15.63M0.0%N/A2.177%Search for SEC Filing on Google Icon
5/14/2021Parkman Healthcare Partners LLC75,454$2.25M0.5%N/A0.314%Search for SEC Filing on Google Icon
5/13/2021Barclays PLC20,500$0.61M0.0%N/A0.085%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC26,800$0.80M0.0%-67.0%0.112%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp12,150$0.36M0.0%-8.4%0.051%Search for SEC Filing on Google Icon
5/12/2021JPMorgan Chase & Co.1,302$39K0.0%N/A0.005%Search for SEC Filing on Google Icon
5/11/2021Acadian Asset Management LLC38,460$1.15M0.0%+236.5%0.160%Search for SEC Filing on Google Icon
5/10/2021Moody Aldrich Partners LLC74,060$2.21M0.3%+1.5%0.321%Search for SEC Filing on Google Icon
5/4/2021Victory Capital Management Inc.179,992$5.38M0.0%+6.3%0.780%Search for SEC Filing on Google Icon
4/28/2021US Bancorp DE12,574$0.38M0.0%-3.8%0.054%Search for SEC Filing on Google Icon
4/26/2021KBC Group NV3,750$0.11M0.0%N/A0.016%Search for SEC Filing on Google Icon
2/18/2021Verition Fund Management LLC33,834$0.61M0.0%+9.0%0.191%Search for SEC Filing on Google Icon
2/16/2021Captrust Financial Advisors3,000$54K0.0%N/A0.017%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC81,200$1.46M0.0%+36.5%0.459%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp13,270$0.24M0.0%N/A0.075%Search for SEC Filing on Google Icon
2/5/2021US Bancorp DE13,073$0.24M0.0%N/A0.074%Search for SEC Filing on Google Icon
2/1/2021Atlas Venture Advisors Inc.612,696$11M2.5%-53.1%3.462%Search for SEC Filing on Google Icon
2/1/2021Victory Capital Management Inc.169,250$3.04M0.0%+11.5%0.956%Search for SEC Filing on Google Icon
11/16/2020Point72 Asset Management L.P.1,363,151$25.97M0.1%+240.4%7.703%Search for SEC Filing on Google Icon
11/16/2020Samlyn Capital LLC418,482$7.97M0.1%N/A2.365%Search for SEC Filing on Google Icon
11/13/2020Morgan Stanley3,989$76K0.0%+14.8%0.023%Search for SEC Filing on Google Icon
11/12/2020Atlas Venture Advisors Inc.1,306,965$24.90M4.2%-4.1%7.386%Search for SEC Filing on Google Icon
11/9/2020Victory Capital Management Inc.151,730$2.89M0.0%-26.9%0.857%Search for SEC Filing on Google Icon
11/5/2020California Public Employees Retirement System20,345$0.39M0.0%+8.5%0.115%Search for SEC Filing on Google Icon
8/24/2020FMR LLC211,444$3.28M0.0%N/A1.195%Search for SEC Filing on Google Icon
8/14/2020Advisor Group Holdings Inc.34,100$0.54M0.0%+34,000.0%0.193%Search for SEC Filing on Google Icon
8/13/2020FMR LLC211,444$3.28M0.0%N/A1.195%Search for SEC Filing on Google Icon
7/31/2020UBS Group AG2,285$36K0.0%N/A0.013%Search for SEC Filing on Google Icon
5/15/2020Pentwater Capital Management LP12,500$0.17M0.0%-76.2%0.071%Search for SEC Filing on Google Icon
5/15/2020Squarepoint Ops LLC13,108$0.18M0.0%N/A0.074%Search for SEC Filing on Google Icon
5/15/2020Morgan Stanley3,255$44K0.0%+32,450.0%0.018%Search for SEC Filing on Google Icon
5/12/2020Victory Capital Management Inc.219,734$3.21M0.0%+62.2%1.242%Search for SEC Filing on Google Icon
5/4/2020Victory Capital Management Inc.219,734$3.21M0.0%+62.2%1.241%Search for SEC Filing on Google Icon
2/14/2020Point72 Asset Management L.P.382,499$3.61M0.0%N/A2.161%Search for SEC Filing on Google Icon
2/13/2020Laurion Capital Management LP74,290$0.70M0.0%-18.0%0.420%Search for SEC Filing on Google Icon
2/6/2020Victory Capital Management Inc.135,496$1.28M0.0%-2.9%0.766%Search for SEC Filing on Google Icon
2/4/2020Victory Capital Management Inc.157,635$1.72M0.0%+13.0%0.891%Search for SEC Filing on Google Icon
11/27/2019Millennium Management LLC34,769$0.40M0.0%-76.4%0.196%Search for SEC Filing on Google Icon
8/17/2019SV Health Investors LLC1,915,274$19.27M12.9%N/A10.821%Search for SEC Filing on Google Icon
8/15/2019Victory Capital Management Inc.139,496$1.40M0.0%N/A0.788%Search for SEC Filing on Google Icon
8/14/2019Pentwater Capital Management LP63,822$0.64M0.0%N/A0.361%Search for SEC Filing on Google Icon
8/13/2019Laurion Capital Management LP100,000$1.01M0.0%N/A0.565%Search for SEC Filing on Google Icon
8/7/2019Monashee Investment Management LLC52,900$0.53M0.1%N/A0.299%Search for SEC Filing on Google Icon
8/6/2019Atlas Venture Advisors Inc.1,362,696$13.71M5.7%N/A7.701%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Bicycle Therapeutics logo
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More on Bicycle Therapeutics

Today's Range

Now: $30.00
$29.33
$30.06

50 Day Range

MA: $30.26
$27.00
$32.28

52 Week Range

Now: $30.00
$15.20
$33.20

Volume

43,764 shs

Average Volume

139,970 shs

Market Capitalization

$722.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Bicycle Therapeutics?

Bicycle Therapeutics' top insider investors include:
  1. Kevin Lee (CEO)
  2. Nicholas Keen (Insider)
  3. Pierre Legault (Director)
  4. Lee Kalowski (CFO)
  5. Plc Glaxosmithkline (Major Shareholder)

Who are the major institutional investors of Bicycle Therapeutics?

Bicycle Therapeutics' top institutional investors include:
  1. Janus Henderson Group PLC — 7.05%
  2. Point72 Asset Management L.P. — 6.57%
  3. Logos Global Management LP — 3.33%
  4. FIL Ltd — 2.18%
  5. Verition Fund Management LLC — 1.00%
  6. Victory Capital Management Inc. — 0.78%

Which major investors are selling Bicycle Therapeutics stock?

During the last quarter, BCYC stock was sold by these institutional investors:
  1. Renaissance Technologies LLC
  2. Morgan Stanley
  3. Bank of New York Mellon Corp
  4. US Bancorp DE
During the previous year, company insiders that have sold Bicycle Therapeutics company stock include:
  1. Kevin Lee (CEO)
  2. Nicholas Keen (Insider)
  3. Pierre Legault (Director)
  4. Lee Kalowski (CFO)
  5. Plc Glaxosmithkline (Major Shareholder)

Which major investors are buying Bicycle Therapeutics stock?

During the previous quarter, BCYC stock was acquired by institutional investors including:
  1. Janus Henderson Group PLC
  2. Logos Global Management LP
  3. FIL Ltd
  4. Verition Fund Management LLC
  5. Ghost Tree Capital LLC
  6. Point72 Asset Management L.P.
  7. Parkman Healthcare Partners LLC
  8. Acadian Asset Management LLC
To Any American Who Owns a Cell Phone
If you own a cell phone, then mobile service providers hope you never get to see this video that could soon go viral.

His experiment could strike a bad chord with mobile phone companies. But you’ve got to see what this man discovered and what it means for phone users in the weeks ahead.
Click here to see this video before it's removed